Teva Stock Hits New 52-Week High

As seen on the 24/7 Wall St. homepage on November 9, 2026.

TEVA Teva
52-week high
$42.99
+0.89% vs prior 52-week high · Nov 6, 2026
$44$34$23

Teva's $42.99 close tops the high it set three sessions earlier by 0.89%, capping a climb from $24.26 a year ago. The generic drugmaker is now held by 40 ETFs, so the grind higher is lifting broad funds too.

Before the move last 24 hours
  1. Earnings release
    Related company: TTWO

    TTWO Q2 2027 earnings filed

    SEC EDGAR

Mentioned: TEVA, TEVJF

Sponsored

Related Market Updates

TEVA Teva
Q3 2026
EPS
$0.86
est $0.73 +17.8%
Revenue
$4.39B
est $4.24B +3.6%

Teva's innovative brands AUSTEDO, AJOVY and UZEDY grew 33% in local currency, offsetting the lenalidomide-driven slide in U.S. generics revenue. Both lines came in ahead of expectations, and management raised full-year revenue guidance to $16.7 to $17.0 billion.

Read more